In NPM1-mutated AML patients, cytarabine efficacy is comparable to anthracycline efficacy due to cytarabine’s role in inhibiting DNA replication and the capacity of NPM1 to regulate transcriptional processes. This evidence concerns the gene NPM1 and acute myeloid leukemia.